Olatorepatide clinical trials
Also written HS-20094.
How each study uses olatorepatide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the olatorepatide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test olatorepatide.
- Nov 2026Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the USPhase 2 · Regeneron Pharmaceuticals
Studies
Open first, then newest update. How each study uses olatorepatide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or ObesityRecruitingPhase 2Regeneron PharmaceuticalsNCT07830329Written as Olatorepatide
- Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesRecruitingPhase 2Regeneron PharmaceuticalsNCT07685808Written as Olatorepatide
- Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without DiabetesNot yet recruitingPhase 3Regeneron PharmaceuticalsNCT07896265Written as Olatorepatide
- Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the USActive, not recruitingPhase 2Regeneron PharmaceuticalsNCT07431086Written as Olatorepatide
Codes
What other systems call olatorepatide · ClinicalTrials.gg INT015990
- UNII (FDA) AB29LD7VUQOLATOREPATIDEOne source FDA
- NCI Thesaurus C206956OlatorepatideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | AB29LD7VUQ | OLATOREPATIDE | One source FDA |
| NCI Thesaurus | C206956 | Olatorepatide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.